Bellicum announces $25.0 million underwritten offering priced at-the-market

Houston, oct. 29, 2020 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined effective price of $6.025. the offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of bellicum's existing healthcare-dedicated institutional investors.
BLCM Ratings Summary
BLCM Quant Ranking